Literature DB >> 18615474

Recellularization of biological heart valves with human vascular cells: in vitro hemocompatibility assessment.

Simon Schopka1, Franz-Xaver Schmid, Stephan Hirt, Dietrich E Birnbaum, Christof Schmid, Karla Lehle.   

Abstract

Coverage of cardiovascular bioprostheses with autologous endothelium is used for the purpose of improving blood compatibility. The aim of our study was to analyze endothelialization potential of glutaraldehyde-fixed heart valves, cellular functions of seeded endothelial cells (EC), and the impact of a two-stage seeding protocol using human vascular fibroblasts (FB) and EC from saphenous veins (HSVEC) on cellular functional properties in vitro. Adherence and morphology of adhered cells were assessed by scanning electronic microscopy and immunohistochemistry. Reproducible, complete surface coverage with EC was established on decellularized and glutaraldehyde-fixed bovine pericardium. Analyzing functional properties of cells directly adhered to biomaterial revealed nonproliferative cells, which were capable of inflammatory stimulation in terms of TNF-induced increase in interleukin-6 secretion and adhesion of inflammatory cells. Furthermore, EC showed sustained antithrombotic properties quantified by platelet adhesion onto EC and prostacyclin secretion by EC. Preseeding with vascular fibroblasts using a two-stage seeding protocol induced EC proliferation and improved inflammatory and anti-thrombotic functions. Cardiovascular biomaterials differ significantly in their potential to allow for adhesion of human EC. Successfully endothelialized biomaterial, however, revealed cellular properties which are likely to be favorable to improving performance of biomaterials. Two-stage seeding adds regenerative potential and improves cell functions of adherent EC. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18615474     DOI: 10.1002/jbm.b.31159

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  8 in total

1.  CD133 antibody conjugation to decellularized human heart valves intended for circulating cell capture.

Authors:  John D Vossler; Young Min Ju; J Koudy Williams; Steven Goldstein; James Hamlin; Sang Jin Lee; James J Yoo; Anthony Atala
Journal:  Biomed Mater       Date:  2015-09-03       Impact factor: 3.715

2.  Antibiotic modification of native grafts: improving upon nature's scaffolds.

Authors:  Constantinos Ketonis; Christopher S Adams; Stephanie Barr; Amiethab Aiyer; Irving M Shapiro; Javad Parvizi; Noreen J Hickok
Journal:  Tissue Eng Part A       Date:  2010-06       Impact factor: 3.845

Review 3.  Paediatric nanofibrous bioprosthetic heart valve.

Authors:  Mehrdad Namdari; Babak Negahdari; Ali Eatemadi
Journal:  IET Nanobiotechnol       Date:  2017-08       Impact factor: 1.847

4.  Sequential use of human-derived medium supplements favours cardiovascular tissue engineering.

Authors:  Paul W Riem Vis; Joost P G Sluijter; R Sarita Soekhradj-Soechit; Lex A van Herwerden; Jolanda Kluin; Carlijn V C Bouten
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

5.  A Pulsatile Bioreactor for Conditioning of Tissue-Engineered Cardiovascular Constructs under Endoscopic Visualization.

Authors:  Fabian König; Trixi Hollweck; Stefan Pfeifer; Bruno Reichart; Erich Wintermantel; Christian Hagl; Bassil Akra
Journal:  J Funct Biomater       Date:  2012-07-19

6.  The effect of Heparin-VEGF multilayer on the biocompatibility of decellularized aortic valve with platelet and endothelial progenitor cells.

Authors:  Xiaofeng Ye; Haozhe Wang; Jingxin Zhou; Haiqing Li; Jun Liu; Zhe Wang; Anqing Chen; Qiang Zhao
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

7.  Preparation and characterization of acellular adipose tissue matrix using a combination of physical and chemical treatments.

Authors:  Mei Song; Yi Liu; Ling Hui
Journal:  Mol Med Rep       Date:  2017-10-24       Impact factor: 2.952

8.  Recellularization of a novel off-the-shelf valve following xenogenic implantation into the right ventricular outflow tract.

Authors:  Ryan S Hennessy; Jason L Go; Rebecca R Hennessy; Brandon J Tefft; Soumen Jana; Nicholas J Stoyles; Mohammed A Al-Hijji; Jeremy J Thaden; Sorin V Pislaru; Robert D Simari; John M Stulak; Melissa D Young; Amir Lerman
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.